Recursion director Dean Y. Li receives 3,378 shares

The award was issued under Recursion Pharmaceuticals' Outside Director Compensation Policy, with reported positions also held through two trusts.

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. director Dean Y. Li acquired 3,378 shares of Class A common stock on October 1, 2026, as an award issued pursuant to the issuer’s Outside Director Compensation Policy. His directly held position following the award was 1,476,707 shares. The report also lists 1,422,048 shares held by Dean Y. Li Revocable Trust and 421,000 shares held by Dean Y. Li 2021 Family Trust.

Insider Trade Summary

Grant/Award: 3,378 shares

Grant/Award 3 txns

Insider Li Dean Y

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock F1	3,378	$0.00	$0.00
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,476,707 shares (Direct); Class A Common Stock — 1,422,048 shares (Indirect, By Dean Y. Li Revocable Trust); Class A Common Stock — 421,000 shares (Indirect, By Dean Y. Li 2021 Family Trust)

Footnotes (1)

1. F1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Key Figures

Award shares acquired: 3,378 shares Direct shares following award: 1,476,707 shares Shares held by Dean Y. Li Revocable Trust: 1,422,048 shares +1 more

4 metrics

Award shares acquired 3,378 shares October 1, 2026

Direct shares following award 1,476,707 shares October 1, 2026

Shares held by Dean Y. Li Revocable Trust 1,422,048 shares October 1, 2026

Shares held by Dean Y. Li 2021 Family Trust 421,000 shares October 1, 2026

Key Terms

Outside Director Compensation Policy, Revocable Trust, Family Trust

3 terms

Outside Director Compensation Policy financial

"issued pursuant to the Issuer's Outside Director Compensation Policy"

Revocable Trust technical

"By Dean Y. Li Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Family Trust technical

"By Dean Y. Li 2021 Family Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did RXRX director Dean Y. Li receive?

Dean Y. Li acquired 3,378 shares of Class A common stock on October 1, 2026, as an award pursuant to Recursion Pharmaceuticals' Outside Director Compensation Policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 06:17 PM Accepted by SEC EDGAR 10/02/2026 - 06:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Li Dean Y

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2026		A(1)		3,378	A	$0	1,476,707	D
Class A Common Stock								1,422,048	I	By Dean Y. Li Revocable Trust
Class A Common Stock								421,000	I	By Dean Y. Li 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)